Table II.
Expression profile of Prdx1 in ESCC, adjacent carcinoma and normal tissues including the score and intensity.
| Score and intensity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| 1 | 2 | ||||||||
|
|
|
||||||||
| Type of tissues | No. tested | Positive, n (%) | 0 | + | ++ | +++ | + | ++ | +++ |
| ESCC | 16 | 16 (100) | 0 | 2 | 2 | 1 | 4 | 3 | 4 |
| Adjacent carcinoma | 14 | 9 (64.3) | 5 | 1 | 3 | 2 | 0 | 0 | 3 |
| Normal | 12 | 6 (50.0) | 5 | 1 | 1 | 0 | 3 | 0 | 2 |
P<0.01, ESCC compared to normal tissue; P>0.05, adjacent carcinoma to normal tissue; P<0.05, ESCC to adjacent carcinoma. Scoring criteria: 0, 0% of the total cell population is positive; 1, 1–50% of the total cell population is positive; 2, 50–100% of the total cell population is positive. +, weak intensity; ++, mild intensity; +++, strong intensity. Prdx1, peroxiredoxin 1; ESCC, esophageal squamous cell carcinoma.